
Recombinant DNA

by Martin Perez Comisso & Esmerelda Parker

> HSD 501 July 8th, 2017

Recombinant DNA



Applications

human insulin

agriculture

gene therapy




Key Players

Paul Berg







Key Players

Genentech Stanford

Stanley Cohen

Scientific Concerns

harmless microbes — human pathogens

antibiotic resistant

toxin producing

cancer causing





Public Fears



Moratorium of 1974








The committee was particularly concerned that introduced genes could change normally innocuous microbes into cancer-causing agents or into human pathogens, resistant to antibiotics or able to produce dangerous toxins.




Hurlbut, J. B., Jasanoff, S., & Kim, S. (2015). Remembering the future: Science, law, and the legacy of Asilomar. *Dreamscapes of Modernity. University of Chicago Press: Chicago*, 126-151.

Pictures of National Academy of Science Archive. Retrieved of MIT Library page https://libraries.mit.edu/archives/exhibits/asilomar/index1.html#2


Paul Berg (Stanford) + 140...



Legislative Reaction





Executive Governance After Asilomar



Berg, P., & Mertz, J. E. (2010). Personal reflections on the origins and emergence of recombinant DNA technology. *Genetics*, 184(1), 9-17. Wivel, N. A. (2014). Historical perspectives pertaining to the NIH recombinant DNA advisory committee. *Human gene therapy*, 25(1), 19-24.

Executive Governance After Asilomar





Paul Berg

Berg, P. (2008). Meetings that changed the world: Asilomar 1975: DNA modification secured. Nature, 455(7211), 290-291. Chicago